-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! Shijiazhuang Sihua Pharmaceutical Group’s Fat-Soluble Vitamin Injection (II) Has Been Approved
Category:
发布时间：2026-03-13
【概要描述】
Innovative achievements are already bearing fruit in early spring. On March 13, the Class 3 liposoluble vitamin injection (II) developed and submitted for approval by Shijiazhuang Sihua Pharmaceutical Group received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation, making the company one of the first in China to obtain such approval. This marks the group’s sixth newly approved dosage-form product so far this year.
Innovative achievements are already bearing fruit in early spring. On March 13, the Class 3 liposoluble vitamin injection (II) developed and submitted for approval by Shijiazhuang Sihua Pharmaceutical Group received production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This marks the group’s sixth newly approved dosage-form product so far this year.
According to available information, the fat-soluble vitamin injection (II) is indicated to meet the daily physiological requirements of adults and children aged 11 years and older for fat-soluble vitamins A, D₂, E, and K₁.
The approval of this fat-soluble vitamin injection (II) further strengthens the Group’s product portfolio in the areas of nutritional supplementation, as well as minerals, electrolytes, and acid–base balance. To date, the Group has a total of 171 drug varieties comprising 223 dosage forms that have either passed or are deemed to have passed the bioequivalence and therapeutic equivalence evaluation for generic drugs, thereby continuously enhancing product accessibility.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091